Literature DB >> 2297233

[Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].

T Furuta1, T Yokokura.   

Abstract

Effect of administration schedules on the antitumor activity of CPT-11, a novel derivative of camptothecin, against mouse L 1210 leukemia and Meth A fibrosarcoma was investigated. At the same total dose, CPT-11 showed more significant antitumor activity by repeated administration. The most effective administration intervals were 5 days for L 1210 and 1 to 3 days for Meth A. CPT-11 showed a considerable antitumor activity by the repeated treatments for 2 or 3 times of continuous administration for 3 or 5 days.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297233

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  5 in total

Review 1.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

2.  Clinical studies of irinotecan alone and in combination with cisplatin.

Authors:  M Fukuoka; N Masuda
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.

Authors:  Gayle S Jameson; John T Hamm; Glen J Weiss; Carlos Alemany; Stephen Anthony; Michele Basche; Ramesh K Ramanathan; Mitesh J Borad; Raoul Tibes; Allen Cohn; Ioana Hinshaw; Robert Jotte; Lee S Rosen; Ute Hoch; Michael A Eldon; Robert Medve; Katrina Schroeder; Erica White; Daniel D Von Hoff
Journal:  Clin Cancer Res       Date:  2012-11-07       Impact factor: 12.531

Review 4.  Current perspectives on camptothecins in cancer treatment.

Authors:  J Dancey; E A Eisenhauer
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

5.  A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

Authors:  N E Schoemaker; I E L M Kuppens; V Moiseyenko; B Glimelius; M Kjaer; H Starkhammer; D J Richel; R Smaaland; K Bertelsen; J P Poulsen; E Voznyi; J Norum; D Fennelly; K M Tveit; A Garin; G Gruia; A Mourier; D Sibaud; P Lefebvre; J H Beijnen; J H M Schellens; W W ten Bokkel Huinink
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.